4SC-202 in Combination with Pembrolizumab in Patients with Cutaneous Melanoma - The SENSITIZE Study
- Conditions
- nresectable Stage III/Metastatic Stage IV CutaneousMelanomaMedDRA version: 20.0Level: LLTClassification code 10027152Term: Melanoma of skin (malignant)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2017-001050-33-IT
- Lead Sponsor
- 4SC AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Signed informed consent must be obtained prior to any study specific procedure.
1. Male or female patients, age = 18 years (at screening)
2. ECOG PS 0-1
3. Patients with unresectable stage III or stage IV cutaneous melanoma, as per AJCC
staging system (Version 8) (must have been histologically confirmed at least once
during course of disease)
4. Patients with metastatic tumor of unknown primary site and histology of melanoma
are eligible
5.Patients must be primary refractory or non-responding to the last prior anti-PD-1 therapy (either as monotherapy or in combination with Ipilimumab)
The following definitions apply:
i.Primary refractory: Patients not achieving a response of CR, PR or SD (i.e. not achieving disease control)
ii.Non-responding: Patients not having achieved a response of CR or PR but having achieved SD
6.Patients must have progressed during last prior anti-PD-1 mono therapy or Ipilimumab/anti-PD-1 combination therapy, and within 6 months after the last dose of either Nivolumab or Pembrolizumab
7.Patients must have had anti-PD-1 mono therapy or Ipilimumab/anti-PD-1 combination therapy as the last systemic cancer directed treatment consisting of at least two administrations of either Nivolumab or Pembrolizumab and must have received the last anti-PD-1 administration within 6 months prior to ICF signature
8. Patients must have been tested for BRAF V600 mutation status
9. Patients with BRAF-mutated melanoma must have had a BRAF-mutation directed therapy, unless they were not considered eligible (e.g. due to contraindications) for such treatment
10. Measurable disease by CT or MRI per irRECIST 1.1 criteria, with longest diameter for
non-nodal lesions = 10 mm and = 15 mm in short axis for nodal lesions
11.At least one tumor site (either primary site or metastasis) must be accessible for sequential biopsies and the patient must consent to 2 mandatory biopsies. This requirement is not applicable for continuous dosing schedules and may be waived by the sponsor in other individual cases
12. Females of Childbearing Potential must agree to use highly effective contraception from screening to at least four months after the last dose of Pembrolizumab or 4SC-202 (whatever is later)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 18
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 18
1. Patients not consenting to use adequate contraception as required per protocol
2. Patients currently participating or who have participated in a study of an investigational
agent, or who are using an investigational device or have done so within 28 days of the
first dose of study drug.
3.Patients who achieved a CR or PR, during or after last prior anti-PD-1 mono- or anti-CTLA-4/anti-PD-1 combination therapy
4. Life expectancy below 3 months
5. Patients with uveal or mucosal melanoma
6. Patients with symptomatic brain metastases/CNS involvement
7. Patients with inadequate organ function, defined as: a) Absolute neutrophil count (ANC) < 1500/µL
b) Hemoglobin (Hb) < 9 g/dL
c) Platelet count < 100,000/µL
d) Potassium outside of normal limits and not correctable with supplements
e) Serum creatinine > 1.5 x ULN or eGFR < 50 mL/min
f) ALT and/or AST > 2.5 x ULN
g) Serum total bilirubin > 1.5 x ULN
h) LDH > 5 x ULN
8. Remaining relevant toxicity (excluding alopecia, fatigue) to previous therapy has not resolved to Grade 1
9. Patients with a history of anti-PD-1 / immune-related adverse drug reactions of Grade 4 or Grade 3 and a high risk of re-occurrence
10. Prior treatment with a HDAC or LSD1 inhibitor or both
11. Prior treatment with anti-PD-L1 or anti-PD-L2 agents
12. Patients with precedent systemic anti-cancer therapy including chemotherapy, endocrine therapy, immunotherapy or who use other investigational agents prior to first study drug administration if no wash-out period of 5 half-lives or 4 weeks has been respected before first study drug administration.
13. Therapy with agents known to prolong the QT interval and increase the risk of Torsade des pointes, such as certain antibiotics, antidepressants or neuroleptics
14. Patients who have received a live vaccine within 28 days prior to anticipated first dose of study drug
15. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 14 days of study drug administration.
16. Patients with any immunodeficiency disorder
17. Patients with any active, known or suspected autoimmune disease that might deteriorate when receiving an immunostimulatory agent as judged by the investigator
18. Patients with a marked baseline prolongation of QT/QTc interval; Long-QTSyndrome
19. Patients with any active gastrointestinal disorder that could interfere with the absorption of 4SC-202 (as per judgement of the investigator), such as ulcerative colitis, Crohn’s disease, diabetic gastroparesis, or other syndromes characterized by malabsorption
20. Patients who are unable to take oral medication
21. Patients with a history of or concurrent other malignancies that require active systemic treatment.
22. Patients with any other medical, psychiatric or social condition, which in the opinion of the investigator would preclude participation in the trial, pose an undue medical hazard, interfere with the conduct of the trial or interfere with interpretation of the trial results
23. Women who are pregnant or lactating or who are planning on becoming pregnant during the trial or for 90 days after completion of the trial
24. Patients with known HIV, acute or chronic active hepatitis B or hepatitis C
25. Patients with an active systemic infection
26. Patients with major surgery within the last 4 weeks
27. Patients with history or current evidence of clinically relevant allergies or hypersen
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method